LSE · CLBX.L
CelLBxHealth plc
£0.01£0.00 (0.0%)
CelLBxHealth plc’s quoted price sits in the lower half of its reported 52-week range, 77.68% below the high.
Loading market information…
LSE · GDR.L · GBp
Stock price, earnings
Quote as of Oct 30, 2026, 08:04 AM UTC. Cached market data; not a live quote.
One-year closing-price history · GBp. Historical prices are not a forecast.
Genedrive Plc’s quoted price sits in the lower half of its reported 52-week range, 37.68% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Genedrive Plc’s next earnings report is currently expected on Nov 24, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Genedrive Plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Genedrive Plc, a molecular diagnostics firm established in Manchester, UK, in 2000 (and known as Epistem Holdings Plc until its name change in July 2016), focuses on developing and commercializing innovative point-of-care diagnostic platforms. These solutions cater to a range of applications, including the identification of infectious diseases, genetic profiling, and pathogen detection. At the core of their offerings is the proprietary Genedrive system, a compact polymerase chain reaction (PCR) technology. This advanced platform enables the rapid amplification and detection of nucleic acids from diverse biological samples, such as plasma, sputum, and buccal swabs. The Genedrive platform features several key diagnostic products: the Genedrive HCV ID Kit for qualitative Hepatitis C virus detection; the Genedrive BioPlex, designed for the quick identification of military biothreats from pathogens; and the Genedrive MT-RNR1-ID Kit, a rapid genetic test vital for emergency neonatal care. Complementing these is the Genedrive Connect app, an Android-based mobile application that streamlines data management and facilitates results transmission. Genedrive Plc serves the biotechnology and pharmaceutical sectors globally, with its reach extending throughout the United Kingdom, Europe, the United States, and other international regions. The company has also partnered with Beckman Coulter Life Sciences to automate laboratory PCR testing procedures for COVID-19.
Latest available per-share figures in GBP. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:26 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
£0.01£0.00 (0.0%)
CelLBxHealth plc’s quoted price sits in the lower half of its reported 52-week range, 77.68% below the high.
£0.01+£0.00 (+6.06%)
GENinCode plc’s quoted price sits in the lower half of its reported 52-week range, 85.71% below the high.
£0.01+£0.00 (+4.29%)
Proteome Sciences plc’s quoted price sits in the lower half of its reported 52-week range, 66.82% below the high.
£0.01£0.00 (0.0%)
Cizzle Biotechnology Holdings Plc’s quoted price sits in the lower half of its reported 52-week range, 70.51% below the high.
£0.00£0.00 (0.0%)
N4 Pharma Plc’s quoted price sits in the lower half of its reported 52-week range, 52.5% below the high.
£0.02£0.00 (0.0%)
Cambridge Nutritional Sciences plc’s quoted price sits in the lower half of its reported 52-week range, 44.64% below the high.
£0.00-£0.00 (-12.5%)
Surgical Innovations Group plc’s quoted price sits in the lower half of its reported 52-week range, 41.67% below the high.
£0.06-£0.00 (-1.79%)
Feedback plc’s quoted price sits in the lower half of its reported 52-week range, 63.33% below the high.
